Lv4
680 积分 2023-09-23 加入
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
4个月前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)]
4个月前
已完结
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
4个月前
已完结
皖公网安备34019202002308
